tradingkey.logo
tradingkey.logo
Buscar

Artiva Biotherapeutics Inc

ARTV
Añadir a la lista de seguimiento
4.010USD
+0.050+1.26%
Cierre 11-13 16:00(ET)
196.05MCap. mercado
PérdidaP/E TTM

Acerca de Artiva Biotherapeutics Inc Compañía

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Perfil de Artiva Biotherapeutics Inc

Símbolo de cotizaciónARTV
Nombre de la empresaArtiva Biotherapeutics Inc
Fecha de salida a bolsaJul 19, 2024
Director ejecutivoAslan (Fred)
Número de empleados89
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 19
Dirección5505 Morehouse Drive
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92121
Teléfono18582674467
Sitio Webhttps://www.artivabio.com/
Símbolo de cotizaciónARTV
Fecha de salida a bolsaJul 19, 2024
Director ejecutivoAslan (Fred)

Ejecutivos de Artiva Biotherapeutics Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
345.18K
-18.01%
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
345.18K
-18.01%
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
345.18K
-18.01%
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Chief Medical Officer
168.74K
-0.66%
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Chief Medical Officer
168.74K
-0.66%
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Chief Medical Officer
168.74K
-0.66%
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
148.23K
-2.09%
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
148.23K
-2.09%
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
148.23K
-2.09%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-55.67%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
345.18K
-18.01%
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
345.18K
-18.01%
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
345.18K
-18.01%
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Chief Medical Officer
168.74K
-0.66%
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Chief Medical Officer
168.74K
-0.66%
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Chief Medical Officer
168.74K
-0.66%

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Artiva Biotherapeutics Inc?

Los cinco principales accionistas de Artiva Biotherapeutics Inc son: Dr. Fred Aslan, M.D.

¿Cuántas instituciones poseen acciones de Artiva Biotherapeutics Inc (ARTV)?

A fecha de 2026Q1, 123 instituciones poseen acciones de Artiva Biotherapeutics Inc, con un valor de mercado combinado de aproximadamente 17.01M, lo que representa el 68.82% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -4519850.00.
tradingkey.logo
Advertencia de Riesgo: Nuestro sitio web y aplicación móvil solo proporcionan información general sobre ciertos productos de inversión. Finsights no proporciona, y la provisión de dicha información no debe interpretarse como que Finsights proporciona, asesoramiento financiero o recomendación para cualquier producto de inversión.
Los productos de inversión están sujetos a riesgos de inversión significativos, incluida la posible pérdida del monto principal invertido y pueden no ser adecuados para todos. El rendimiento pasado de los productos de inversión no es indicativo de su rendimiento futuro.
Finsights puede permitir que anunciantes o afiliados de terceros coloquen o entreguen anuncios en nuestro sitio web o aplicación móvil o en cualquier parte de los mismos y puede ser compensado por ellos en función de su interacción con los anuncios.
© Derechos de autor: FINSIGHTS MEDIA PTE. LTD. Todos los derechos reservados.